Restore Medical has secured a significant $23 million in Series B funding to support the development of its flagship product, ContraBand, which treats heart failure patients. This funding will be used for a European feasibility study and a US-based clinical trial. Notably, ContraBand received FDA Breakthrough Device designation last year.
In 2022, Restore Medical completed a clinical study with ContraBand, enrolling 15 patients across five European hospitals. The company also received $2.9 million in funding and $11.6 million in equity investment to enhance the device’s development and investigate its safety and efficacy.
The Vigilant Fox
@VigilantFox
·
Jun 7 DMSO shields heart cells during and after heart attacks, reduces tissue death, prevents cardiac rupture, and even helps stem cells regenerate heart tissue.It boosts circulation and can restart weak hearts without even touching heart rhythm.But Big Pharma said… pass.
Ahmed Bennis MD
@drbennisahmed
·
Jul 5 Leadless Ultrasound-Based Cardiac Resynchronization System in Heart FailureThe SOLVE-CRT study has demonstrated that leadless LV endocardial pacing with the WiSE CRT system is associated with a reduction in LVESV in patients with HF. This novel system may represent an
HealthIT Policy
@HITpol
·
22h Restore Medical secures $23M for heart failure studies http://dlvr.it/TLpSFr in
@MobiHealthNews
MobiHealthNews
@MobiHealthNews
·
21h Restore Medical secures $23M for heart failure studies https://mobihealthnews.com/news/restore-medical-secures-23m-heart-failure-studies?utm_source=dlvr.it&utm_medium=twitter… #DigitalHealth
The Heart
@ZHeart11768530
·
Jul 6 Cardiorenal Disease and Heart Failure with Preserved Ejection Fraction: Two Sides of the Same Coin #2025Review #openaccess
https://karger.com/crm/article/15/1/108/918900/Cardiorenal-Disease-and-Heart-Failure-with…
#FOAMed #MedEd #medstudent #paramedic #Cardiology #CardioEd #medtwitter #meded
Startup Nation Central
@sncentral_
·
Jul 8 Congratulations to
@RestoreMedical
, an Israeli clinical-stage medical technology company, for closing a $23 million Series B round to advance its minimally invasive device for treating heart failure, a condition that remains one of the world’s leading causes of death and
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
